Keytruda is the first anti-PD-1 monoclonal antibody therapy approved for patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer.
List view / Grid view
Merck Research Laboratories
7 March 2013 | By Merck
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Roger M. Perlmutter, M.D., Ph.D., as executive vice president and president of Merck Research Laboratories (MRL), effective April 15. Dr. Perlmutter will succeed Peter S. Kim, Ph.D., who has served in the role…
24 March 2006 | By Maria L. Garcia and Gregory J. Kaczorowski,Department of Ion Channels, Merck Research Laboratories
The extensive amount of knowledge accumulated over the last few years on the physiological importance of ion channels and, consequently, the broad expectation that drugs which modify the activity of these proteins could have therapeutic benefit, has triggered resurgence in the study of ion channels in both academic and pharmaceutical…
22 August 2005 | By James Herrington and Owen B. McManus, Department of Ion Channels, Laszlo Kiss, Pain Research, Merck Research Laboratories
Ion channels are membrane spanning proteins with narrow hydrophilic pores that support the passive flux of inorganic ions across the cell membrane.